CIK 0001492422
APLS Apellis Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Mar 13, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
21
with a Form 4 at this company
Signals
Open-market buys and sells at Apellis Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $8,153 368 shares | -0% | - | |
| 41Moderate | David O. Watson General Counsel sell | $170k 7,832 shares | -8% | - | |
| 49Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $224k 10,287 shares | -10% | - | |
| 41Moderate | Nur Nicholson Chief Technical Officer sell | $168k 7,725 shares | -10% | - | |
| 59Moderate | Cedric Francois Chief Executive Officer sell | $592k 27,192 shares | -9% | - | |
| 41Moderate | Pascal Deschatelets Chief Scientific Officer sell | $129k 5,928 shares | -1% | - | |
| 38Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $73k 3,371 shares | -4% | - | |
| 36Weak | James George Chopas VP/Chief Accounting Officer sell | $45k 2,064 shares | -4% | - | |
| 37Weak | Caroline Baumal Chief Medical Officer sell | $61k 2,797 shares | -3% | - | |
| 37Weak | David O. Watson General Counsel sell | $49k 2,475 shares | -3% | - | |
| 44Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $57k 2,892 shares | -3% | - | |
| 36Weak | Nur Nicholson Chief Technical Officer sell | $44k 2,203 shares | -3% | - | |
| 51Moderate | Cedric Francois Chief Executive Officer sell | $162k 8,182 shares | -3% | - | |
| 30Weak | Pascal Deschatelets Chief Scientific Officer sell | $18k 909 shares | -0% | - | |
| 35Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $26k 1,334 shares | -2% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $14k 726 shares | -1% | - | |
| 36Weak | Caroline Baumal Chief Medical Officer sell | $37k 1,882 shares | -2% | - | |
| 41Moderate | David O. Watson General Counsel sell | $128k 5,780 shares | -6% | - | |
| 46Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $86k 3,856 shares | -3% | - | |
| 37Weak | Nur Nicholson Chief Technical Officer sell | $58k 2,618 shares | -3% | - | |
| 53Moderate | Cedric Francois Chief Executive Officer sell | $226k 10,186 shares | -3% | - | |
| 37Weak | Pascal Deschatelets Chief Scientific Officer sell | $51k 2,277 shares | -0% | - | |
| 36Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $39k 1,780 shares | -2% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $19k 873 shares | -2% | - | |
| 38Weak | Caroline Baumal Chief Medical Officer sell | $77k 3,020 shares | -3% | - | |
| 5Weak | David O. Watson General Counsel sell | $122k 5,000 shares | -5% | - | |
| 5Weak | David O. Watson General Counsel sell | $100k 5,000 shares | -4% | - | |
| 16Weak | Timothy Eugene Sullivan Chief Financial Officer sell | $280k 10,000 shares | -8% | - | |
| 21Weak | David O. Watson General Counsel sell | $126k 5,000 shares | -4% | - | |
| 51Moderate | A. Sinclair Dunlop director sell | $738k 31,092 shares | -89% | - | |
| 34Weak | A. Sinclair Dunlop director sell | $702k 31,092 shares | -48% | - | |
| 41Moderate | A. Sinclair Dunlop director sell | $714k 31,092 shares | -31% | - | |
| 20Weak | David O. Watson General Counsel sell | $122k 5,000 shares | -4% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $4,572 189 shares | -0% | - | |
| 58Moderate | David O. Watson General Counsel sell | $523k 20,000 shares | -29% | - | |
| 37Weak | Timothy Eugene Sullivan Chief Financial Officer sell | $1.2M 42,729 shares | -30% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $15k 548 shares | -1% | - | |
| 75Notable | Cedric Francois Chief Executive Officer sell | $6.4M 225,000 shares | -42% | - | |
| 14Weak | David O. Watson General Counsel sell | $139k 5,000 shares | -4% | - | |
| 13Weak | David O. Watson General Counsel sell | $98k 5,000 shares | -4% | - | |
| 14Weak | Cedric Francois Chief Executive Officer sell | $399k 19,725 shares | -6% | - | |
| 33Weak | Cedric Francois Chief Executive Officer sell | $2.8M 139,365 shares | -29% | - | |
| 5Weak | David O. Watson General Counsel sell | $94k 5,000 shares | -4% | - | |
| 23Weak | James George Chopas VP/Chief Accounting Officer sell | $4,543 183 shares | -0% | - | |
| 34Weak | David O. Watson General Counsel sell | $140k 5,569 shares | -4% | - | |
| 30Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $10k 363 shares | -0% | - | |
| 30Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $11k 365 shares | -0% | - | |
| 49Moderate | Cedric Francois Chief Executive Officer sell | $83k 2,824 shares | -1% | - | |
| 30Weak | Pascal Deschatelets Chief Scientific Officer sell | $24k 826 shares | -0% | - | |
| 30Weak | Jeffrey Eisele Chief Development Officer sell | $8,208 278 shares | -1% | - | |
| 30Weak | Karen Lewis Chief People Officer sell | $11k 364 shares | -1% | - | |
| 30Weak | Nur Nicholson Chief Technical Officer sell | $24k 825 shares | -1% | - | |
| 37Weak | Timothy Eugene Sullivan Chief Financial Officer sell | $16k 546 shares | -0% | - | |
| 30Weak | Adam J. Townsend Chief Commercial Officer sell | $21k 695 shares | -1% | - | |
| 30Weak | David O. Watson General Counsel sell | $21k 695 shares | -0% | - | |
| 36Weak | James George Chopas VP/Chief Accounting Officer sell | $33k 1,096 shares | -2% | - | |
| 36Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $42k 1,396 shares | -2% | - | |
| 40Moderate | Pascal Deschatelets Chief Scientific Officer sell | $120k 3,948 shares | -0% | - | |
| 36Weak | Jeffrey Eisele Chief Development Officer sell | $39k 1,291 shares | -2% | - | |
| 56Moderate | Cedric Francois Chief Executive Officer sell | $412k 13,551 shares | -3% | - | |
| 37Weak | Karen Lewis Chief People Officer sell | $53k 1,751 shares | -2% | - | |
| 40Moderate | Nur Nicholson Chief Technical Officer sell | $120k 3,948 shares | -4% | - | |
| 47Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $94k 3,088 shares | -2% | - | |
| 40Moderate | Adam J. Townsend Chief Commercial Officer sell | $101k 3,323 shares | -4% | - | |
| 40Moderate | David O. Watson General Counsel sell | $101k 3,323 shares | -2% | - | |
| 37Weak | Caroline Baumal Chief Medical Officer sell | $56k 1,853 shares | -3% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $21k 715 shares | -2% | - | |
| 36Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $37k 1,235 shares | -2% | - | |
| 30Weak | Pascal Deschatelets Chief Scientific Officer sell | $22k 750 shares | -0% | - | |
| 52Moderate | Cedric Francois Chief Executive Officer sell | $180k 6,007 shares | -2% | - | |
| 36Weak | Karen Lewis Chief People Officer sell | $37k 1,241 shares | -3% | - | |
| 38Weak | Nur Nicholson Chief Technical Officer sell | $64k 2,145 shares | -4% | - | |
| 44Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $52k 1,730 shares | -2% | - | |
| 38Weak | Adam J. Townsend Chief Commercial Officer sell | $66k 2,201 shares | -2% | - | |
| 38Weak | David O. Watson General Counsel sell | $66k 2,201 shares | -2% | - | |
| 30Weak | James George Chopas VP/Chief Accounting Officer sell | $22k 783 shares | -2% | - | |
| 36Weak | Mark Jeffrey DeLong Chief Business & Strat Officer sell | $46k 1,599 shares | -3% | - | |
| 38Weak | Pascal Deschatelets Chief Scientific Officer sell | $66k 2,288 shares | -0% | - | |
| 30Weak | Jeffrey Eisele Chief Development Officer sell | $7,577 264 shares | -0% | - | |
| 52Moderate | Cedric Francois Chief Executive Officer sell | $179k 6,247 shares | -2% | - | |
| 36Weak | Karen Lewis Chief People Officer sell | $46k 1,599 shares | -3% | - | |
| 38Weak | Nur Nicholson Chief Technical Officer sell | $76k 2,632 shares | -5% | - | |
| 44Moderate | Timothy Eugene Sullivan Chief Financial Officer sell | $62k 2,170 shares | -2% | - | |
| 38Weak | Adam J. Townsend Chief Commercial Officer sell | $77k 2,685 shares | -3% | - | |
| 41Moderate | David O. Watson General Counsel sell | $143k 4,965 shares | -4% | - | |
| 40Moderate | Caroline Baumal Chief Medical Officer sell | $95k 2,816 shares | -5% | - | |
| 30Weak | Jeffrey Eisele Chief Development Officer sell | $2,085 63 shares | -0% | - | |
| 34Weak | David O. Watson General Counsel sell | $171k 5,000 shares | -4% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Cedric Francois Chief Executive Officer | GGift Common Stock | -64,869 | $0.00 | $0 | 425,968 | Mar 13, 2026 |
| Mar 11, 2026 | Cedric Francois Chief Executive Officer | GGift Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | +64,869 | $0.00 | $0 | 372,815 | Mar 13, 2026 |
| Feb 27, 2026 | Mikael Dolsten director | AGrant or award Common Stock | +14,312 | $0.00 | $0 | 14,312 | Mar 3, 2026 |
| Feb 27, 2026 | Mikael Dolsten director | AGrant or award Stock Option (Right to Buy)derivative | +24,135 | $20.96 | $506k | 24,135 | Mar 3, 2026 |
| Feb 11, 2026 | Mark Jeffrey DeLong Chief Business & Strat Officer | SOpen-market sale Common Stock | -368 | $22.15 | $8,153 | 114,591 | Feb 13, 2026 |
| Feb 3, 2026 | Cedric Francois Chief Executive Officer | MOption exercise Common Stock | +8,840 | $3.76 | $33k | 490,837 | Feb 5, 2026 |
| Feb 3, 2026 | Cedric Francois Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -8,840 | $0.00 | $0 | 0 | Feb 5, 2026 |
| Jan 28, 2026 | Nur Nicholson Chief Technical Officer | AGrant or award Common Stock | +45,220 | $0.00 | $0 | 116,338 | Jan 30, 2026 |
| Jan 28, 2026 | David O. Watson General Counsel | AGrant or award Common Stock | +55,986 | $0.00 | $0 | 144,517 | Jan 30, 2026 |
| Jan 28, 2026 | Cedric Francois Chief Executive Officer | AGrant or award Common Stock | +195,952 | $0.00 | $0 | 481,997 | Jan 30, 2026 |
| Jan 28, 2026 | Kelley Boucher Chief People Officer | AGrant or award Common Stock | +30,146 | $0.00 | $0 | 127,804 | Jan 30, 2026 |
| Jan 28, 2026 | Timothy Eugene Sullivan Chief Financial Officer | AGrant or award Common Stock | +58,140 | $0.00 | $0 | 152,041 | Jan 30, 2026 |
| Jan 28, 2026 | Pascal Deschatelets Chief Scientific Officer | AGrant or award Common Stock | +25,840 | $0.00 | $0 | 1,177,222 | Jan 30, 2026 |
| Jan 28, 2026 | Leslie Meltzer Chief Research and Development | AGrant or award Common Stock | +45,220 | $0.00 | $0 | 107,024 | Jan 30, 2026 |
| Jan 28, 2026 | Mark Jeffrey DeLong Chief Business & Strat Officer | AGrant or award Common Stock | +36,606 | $0.00 | $0 | 114,959 | Jan 30, 2026 |
| Jan 28, 2026 | James George Chopas VP/Chief Accounting Officer | AGrant or award Common Stock | +16,150 | $0.00 | $0 | 65,955 | Jan 30, 2026 |
| Jan 22, 2026 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stock | -10,287 | $21.77 | $224k | 93,901 | Jan 23, 2026 |
| Jan 22, 2026 | David O. Watson General Counsel | SOpen-market sale Common Stock | -7,832 | $21.77 | $170k | 88,531 | Jan 23, 2026 |
| Jan 22, 2026 | Mark Jeffrey DeLong Chief Business & Strat Officer | SOpen-market sale Common Stock | -3,371 | $21.77 | $73k | 78,353 | Jan 23, 2026 |
| Jan 22, 2026 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock | -27,192 | $21.77 | $592k | 286,045 | Jan 23, 2026 |
| Jan 22, 2026 | Pascal Deschatelets Chief Scientific Officer | SOpen-market sale Common Stock | -5,928 | $21.77 | $129k | 1,151,382 | Jan 23, 2026 |
| Jan 22, 2026 | James George Chopas VP/Chief Accounting Officer | SOpen-market sale Common Stock | -2,064 | $21.77 | $45k | 49,805 | Jan 23, 2026 |
| Jan 22, 2026 | Nur Nicholson Chief Technical Officer | SOpen-market sale Common Stock | -7,725 | $21.77 | $168k | 71,118 | Jan 23, 2026 |
| Jan 22, 2026 | Caroline Baumal Chief Medical Officer | SOpen-market sale Common Stock | -2,797 | $21.77 | $61k | 86,527 | Jan 23, 2026 |
| Jan 20, 2026 | Caroline Baumal Chief Medical Officer | SOpen-market sale Common Stock | -1,882 | $19.79 | $37k | 89,324 | Jan 21, 2026 |
| Jan 20, 2026 | David O. Watson General Counsel | SOpen-market sale Common Stock | -2,475 | $19.79 | $49k | 96,363 | Jan 21, 2026 |
| Jan 20, 2026 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stock | -2,892 | $19.79 | $57k | 104,188 | Jan 21, 2026 |
| Jan 20, 2026 | Nur Nicholson Chief Technical Officer | SOpen-market sale Common Stock | -2,203 | $19.79 | $44k | 78,843 | Jan 21, 2026 |
| Jan 20, 2026 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock | -8,182 | $19.79 | $162k | 313,237 | Jan 21, 2026 |
| Jan 20, 2026 | Pascal Deschatelets Chief Scientific Officer | SOpen-market sale Common Stock | -909 | $19.79 | $18k | 1,157,310 | Jan 21, 2026 |
| Jan 20, 2026 | Mark Jeffrey DeLong Chief Business & Strat Officer | SOpen-market sale Common Stock | -1,334 | $19.79 | $26k | 81,724 | Jan 21, 2026 |
| Jan 20, 2026 | James George Chopas VP/Chief Accounting Officer | SOpen-market sale Common Stock | -726 | $19.79 | $14k | 51,869 | Jan 21, 2026 |
| Jan 13, 2026 | David O. Watson General Counsel | SOpen-market sale Common Stock | -5,780 | $22.19 | $128k | 98,838 | Jan 15, 2026 |
| Jan 13, 2026 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stock | -3,856 | $22.19 | $86k | 107,080 | Jan 15, 2026 |
| Jan 13, 2026 | Nur Nicholson Chief Technical Officer | SOpen-market sale Common Stock | -2,618 | $22.19 | $58k | 81,046 | Jan 15, 2026 |
| Jan 13, 2026 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock | -10,186 | $22.19 | $226k | 321,419 | Jan 15, 2026 |
| Jan 13, 2026 | Pascal Deschatelets Chief Scientific Officer | SOpen-market sale Common Stock | -2,277 | $22.19 | $51k | 1,158,219 | Jan 15, 2026 |
| Jan 13, 2026 | Mark Jeffrey DeLong Chief Business & Strat Officer | SOpen-market sale Common Stock | -1,780 | $22.19 | $39k | 83,058 | Jan 15, 2026 |
| Jan 13, 2026 | James George Chopas VP/Chief Accounting Officer | SOpen-market sale Common Stock | -873 | $22.19 | $19k | 52,595 | Jan 15, 2026 |
| Jan 7, 2026 | David O. Watson General Counsel | MOption exercise Common Stock10b5-1 | +888 | $14.95 | $13k | 104,618 | Jan 9, 2026 |
| Jan 7, 2026 | David O. Watson General Counsel | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -888 | $0.00 | $0 | 14,000 | Jan 9, 2026 |
| Jan 5, 2026 | Caroline Baumal Chief Medical Officer | SOpen-market sale Common Stock | -3,020 | $25.53 | $77k | 91,206 | Jan 6, 2026 |
| Jan 1, 2026 | Paul R. Fonteyne director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 30,666 | Jan 5, 2026 |
| Jan 1, 2026 | Craig A Wheeler director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 24,444 | Jan 5, 2026 |
| Jan 1, 2026 | Keli Walbert director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 17,051 | Jan 5, 2026 |
| Jan 1, 2026 | Stephanie Monaghan O'Brien director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 25,666 | Jan 5, 2026 |
| Jan 1, 2026 | Gerald Chan director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 25,666 | Jan 5, 2026 |
| Jan 1, 2026 | A. Sinclair Dunlop director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 161,567 | Jan 5, 2026 |
| Jan 1, 2026 | Alec Machiels director | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 384,989 | Jan 5, 2026 |
| Jan 1, 2026 | Craig A Wheeler director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | Keli Walbert director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | Paul R. Fonteyne director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | Stephanie Monaghan O'Brien director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | Gerald Chan director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | A. Sinclair Dunlop director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jan 1, 2026 | Alec Machiels director | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Dec 16, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $24.49 | $122k | 103,730 | Dec 18, 2025 |
| Nov 17, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $20.06 | $100k | 108,730 | Nov 18, 2025 |
| Oct 21, 2025 | Timothy Eugene Sullivan Chief Financial Officer | MOption exercise Common Stock10b5-1 | +10,000 | $10.03 | $100k | 120,936 | Oct 23, 2025 |
| Oct 21, 2025 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $28.03 | $280k | 110,936 | Oct 23, 2025 |
| Oct 21, 2025 | Timothy Eugene Sullivan Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 232,903 | Oct 23, 2025 |
| Oct 16, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $25.22 | $126k | 113,730 | Oct 17, 2025 |
| Jun 24, 2025 | A. Sinclair Dunlop director | JOther Common Stock10b5-1 | -4,787 | $0.00 | $0 | 153,606 | Oct 15, 2025 |
| Oct 10, 2025 | A. Sinclair Dunlop director | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $23.72 | $738k | 3,837 | Oct 15, 2025 |
| Oct 10, 2025 | A. Sinclair Dunlop director | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 0 | Oct 15, 2025 |
| Sep 30, 2025 | A. Sinclair Dunlop director | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $22.58 | $702k | 33,979 | Oct 2, 2025 |
| Sep 30, 2025 | A. Sinclair Dunlop director | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 30,142 | Oct 2, 2025 |
| Sep 19, 2025 | A. Sinclair Dunlop director | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $22.95 | $714k | 68,908 | Sep 19, 2025 |
| Sep 19, 2025 | A. Sinclair Dunlop director | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 65,071 | Sep 19, 2025 |
| Sep 16, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $24.34 | $122k | 118,730 | Sep 18, 2025 |
| Sep 15, 2025 | James George Chopas VP/Chief Accounting Officer | SOpen-market sale Common Stock | -189 | $24.19 | $4,572 | 53,468 | Sep 17, 2025 |
| Sep 10, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stockindirect: Indirect Owner (The David O. Watson Irrevocable Trust of 2023) | -20,000 | $26.17 | $523k | 50,136 | Sep 12, 2025 |
| Sep 8, 2025 | Timothy Eugene Sullivan Chief Financial Officer | MOption exercise Common Stock10b5-1 | +15,000 | $10.03 | $150k | 143,665 | Sep 10, 2025 |
| Sep 8, 2025 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -32,729 | $27.86 | $912k | 110,936 | Sep 10, 2025 |
| Sep 8, 2025 | Timothy Eugene Sullivan Chief Financial Officer | SOpen-market sale Common Stockindirect: The Timothy E Sullivan Irrevocable Trust of 202310b5-1 | -10,000 | $27.83 | $278k | 60,396 | Sep 10, 2025 |
| Sep 8, 2025 | Timothy Eugene Sullivan Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 242,903 | Sep 10, 2025 |
| Sep 2, 2025 | Kelley Boucher Chief People Officer | AGrant or award Common Stock | +30,476 | $0.00 | $0 | 97,658 | Sep 3, 2025 |
| Sep 2, 2025 | James George Chopas VP/Chief Accounting Officer | SOpen-market sale Common Stock | -548 | $28.08 | $15k | 53,657 | Sep 3, 2025 |
| Sep 2, 2025 | Kelley Boucher Chief People Officer | AGrant or award Stock Option (Right to Buy)derivative | +45,766 | $0.00 | $0 | 45,766 | Sep 3, 2025 |
| Aug 26, 2025 | Leslie Meltzer Chief Research and Development | AGrant or award Common Stock | +61,804 | $0.00 | $0 | 61,804 | Sep 2, 2025 |
| Aug 26, 2025 | Leslie Meltzer Chief Research and Development | AGrant or award Stock Option (Right to Buy)derivative | +92,592 | $0.00 | $0 | 92,592 | Sep 2, 2025 |
| Aug 27, 2025 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -175,037 | $28.19 | $4.9M | 357,909 | Aug 29, 2025 |
| Aug 28, 2025 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -49,963 | $28.39 | $1.4M | 307,946 | Aug 29, 2025 |
| Aug 18, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $27.80 | $139k | 123,730 | Aug 19, 2025 |
| Jul 17, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Common Stock10b5-1 | +8,997 | $4.31 | $39k | 351,330 | Jul 18, 2025 |
| Jul 16, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $19.55 | $98k | 128,730 | Jul 18, 2025 |
| Jul 17, 2025 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -19,725 | $20.21 | $399k | 331,605 | Jul 18, 2025 |
| Jul 17, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,997 | $0.00 | $0 | 100,538 | Jul 18, 2025 |
| Jul 14, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Common Stock10b5-1 | +65,203 | $4.31 | $281k | 480,898 | Jul 16, 2025 |
| Jul 14, 2025 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -137,465 | $20.19 | $2.8M | 343,433 | Jul 16, 2025 |
| Jul 15, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Common Stock10b5-1 | +800 | $4.31 | $3,448 | 344,233 | Jul 16, 2025 |
| Jul 15, 2025 | Cedric Francois Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,900 | $20.09 | $38k | 342,333 | Jul 16, 2025 |
| Jul 14, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -65,203 | $0.00 | $0 | 110,335 | Jul 16, 2025 |
| Jul 15, 2025 | Cedric Francois Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -800 | $0.00 | $0 | 109,535 | Jul 16, 2025 |
| Jun 18, 2025 | James George Chopas VP/Chief Accounting Officer | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 54,205 | Jun 20, 2025 |
| Jun 16, 2025 | David O. Watson General Counsel | SOpen-market sale Common Stock10b5-1 | -5,000 | $18.77 | $94k | 133,730 | Jun 18, 2025 |
| Jun 9, 2025 | Mark Jeffrey DeLong Chief Business & Strat Officer | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Jun 9, 2025 | James George Chopas VP/Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +11,250 | $19.39 | $218k | 11,250 | Jun 11, 2025 |
| Jun 9, 2025 | Caroline Baumal Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Jun 9, 2025 | Pascal Deschatelets Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Caroline BaumalChief Medical Officer
- Kelley BoucherChief People Officer
- Gerald Chandirector
- James George ChopasVP/Chief Accounting Officer
- Mark Jeffrey DeLongChief Business & Strat Officer
- Pascal DeschateletsChief Scientific Officer
- Mikael Dolstendirector
- A. Sinclair Dunlopdirector
- Jeffrey EiseleChief Development Officer
- Paul R. Fonteynedirector
- Cedric FrancoisChief Executive Officer
- Karen LewisChief People Officer
- Leslie MeltzerChief Research and Development
- Alec Machielsdirector
- Nur NicholsonChief Technical Officer
- Stephanie Monaghan O'Briendirector
- Timothy Eugene SullivanChief Financial Officer
- Adam J. TownsendChief Commercial Officer
- Craig A Wheelerdirector
- Keli Walbertdirector
- David O. WatsonGeneral Counsel
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.